Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.

Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ, Verheul HM, Hoekstra OS, van den Eertwegh AJ.

Eur Urol. 2016 Sep;70(3):416-26. doi: 10.1016/j.eururo.2015.09.005. Epub 2015 Sep 19. Review.

PMID:
26391636
2.

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Liepe K, Runge R, Kotzerke J.

J Cancer Res Clin Oncol. 2005 Jan;131(1):60-6. Epub 2004 Sep 22.

PMID:
15449184
3.
4.

Strontium 89 therapy for the palliation of pain due to osseous metastases.

Robinson RG, Preston DF, Schiefelbein M, Baxter KG.

JAMA. 1995 Aug 2;274(5):420-4. Review.

PMID:
7542352
5.

Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.

Bauman G, Charette M, Reid R, Sathya J.

Radiother Oncol. 2005 Jun;75(3):258-70. Review.

PMID:
16299924
6.

[Targeted radionuclide therapy for castration-resistant prostate cancer].

Nakamura K, Ohga S, Sasaki T, Baba S, Honda H.

Nihon Rinsho. 2014 Dec;72(12):2181-5. Review. Japanese.

PMID:
25518355
7.

Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.

Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A, Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M, Ronga G.

Clin Ter. 2009;160(3):193-9.

PMID:
19756320
8.

Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.

Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL.

Breast Cancer Res Treat. 2001 Mar;66(2):101-9.

PMID:
11437096
9.

[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].

Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R.

Nuklearmedizin. 2000 Sep;39(6):146-51. German.

PMID:
11057405
10.

Systemic radionuclide therapy in pain palliation.

Liepe K, Runge R, Kotzerke J.

Am J Hosp Palliat Care. 2005 Nov-Dec;22(6):457-64.

PMID:
16323716
11.

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

Picciotto M, Franchina T, Russo A, Ricciardi GRR, Provazza G, Sava S, Baldari S, Caffo O, Adamo V.

Expert Opin Pharmacother. 2017 Jun;18(9):899-908. doi: 10.1080/14656566.2017.1323875. Epub 2017 May 8. Review.

PMID:
28449621
12.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Epub 2014 Sep 17. Review.

13.

186Re-HEDP for metastatic bone pain in breast cancer patients.

Lam MG, de Klerk JM, van Rijk PP.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S162-70. Epub 2004 Apr 29. Review.

PMID:
15118846
14.

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.

Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ.

Nuklearmedizin. 2016 Sep 26;55(5):188-95. doi: 10.3413/Nukmed-0828-16-05. Epub 2016 Jul 22.

PMID:
27443809
15.

89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma.

Baczyk M, Czepczyński R, Milecki P, Pisarek M, Oleksa R, Sowiński J.

Nucl Med Commun. 2007 Apr;28(4):245-50.

PMID:
17325585
16.

A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.

van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, Oprea-Lager DE, Hoekstra OS, van den Berg HP, Los M, Beeker A, Jonker MA, O'Sullivan JM, Verheul HMW, van den Eertwegh AJM.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1319-1327. doi: 10.1007/s00259-017-3673-9. Epub 2017 Apr 18.

PMID:
28421240
17.

Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.

Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA.

Anticancer Agents Med Chem. 2007 Jul;7(4):381-97. Review.

PMID:
17630915
18.

Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.

Pandit-Taskar N, Larson SM, Carrasquillo JA.

J Nucl Med. 2014 Feb;55(2):268-74. doi: 10.2967/jnumed.112.112482. Epub 2013 Dec 16. Review.

19.

Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases.

Maini CL, Sciuto R, Romano L, Bergomi S.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):71-4. Review.

PMID:
16767910
20.

Unsealed source therapy of painful bone metastases: an update.

McEwan AJ.

Semin Nucl Med. 1997 Apr;27(2):165-82. Review.

PMID:
9144858

Supplemental Content

Support Center